- Home
- GOVX vs MTEX Comparison
GOVX vs MTEX Comparison
Compare GOVX & MTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- MTEX
- Stock Information
- Founded
- GOVX 2001
- MTEX 1993
- Country
- GOVX United States
- MTEX United States
- Employees
- GOVX N/A
- MTEX N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- MTEX Medicinal Chemicals and Botanical Products
- Sector
- GOVX Health Care
- MTEX Health Care
- Exchange
- GOVX Nasdaq
- MTEX Nasdaq
- Market Cap
- GOVX 16.8M
- MTEX 18.2M
- IPO Year
- GOVX N/A
- MTEX 1999
- Fundamental
- Price
- GOVX $0.41
- MTEX $9.70
- Analyst Decision
- GOVX Strong Buy
- MTEX
- Analyst Count
- GOVX 2
- MTEX 0
- Target Price
- GOVX $7.00
- MTEX N/A
- AVG Volume (30 Days)
- GOVX 524.6K
- MTEX 24.0K
- Earning Date
- GOVX 11-13-2025
- MTEX 11-12-2025
- Dividend Yield
- GOVX N/A
- MTEX N/A
- EPS Growth
- GOVX N/A
- MTEX N/A
- EPS
- GOVX N/A
- MTEX N/A
- Revenue
- GOVX $3,353,560.00
- MTEX $110,411,000.00
- Revenue This Year
- GOVX N/A
- MTEX N/A
- Revenue Next Year
- GOVX N/A
- MTEX N/A
- P/E Ratio
- GOVX N/A
- MTEX N/A
- Revenue Growth
- GOVX 8.52
- MTEX N/A
- 52 Week Low
- GOVX $0.37
- MTEX $7.50
- 52 Week High
- GOVX $3.01
- MTEX $16.49
- Technical
- Relative Strength Index (RSI)
- GOVX 35.66
- MTEX 55.20
- Support Level
- GOVX $0.37
- MTEX $9.34
- Resistance Level
- GOVX $0.44
- MTEX $9.97
- Average True Range (ATR)
- GOVX 0.03
- MTEX 0.36
- MACD
- GOVX -0.00
- MTEX 0.01
- Stochastic Oscillator
- GOVX 26.59
- MTEX 72.16
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.